<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561964</url>
  </required_header>
  <id_info>
    <org_study_id>L_9079</org_study_id>
    <nct_id>NCT00561964</nct_id>
  </id_info>
  <brief_title>Randomized, Parallel, Comparison, Double-Blind Efficacy &amp; Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria</brief_title>
  <acronym>PRIME</acronym>
  <official_title>Randomized, Parallel, Comparison, Double-Blind Efficacy &amp; Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To evaluate the effects and safety of irbesartan on proteinuria in hypertensive patients with
      type â…¡diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine albumin excretion rate (UAER)</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SeSBP, SeDBP, Total cholesterol, Triglycerides, HDL cholesterol, LDL cholesterol , glycated hemoglobin</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo group: 2 placebo capsules daily as a single morning intake</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting plasma glucose of untreated type II diabetes mellitus patients greater than or
             equal to 7.0 mmol/L, or the time between diagnosis of type II diabetes mellitus and
             treatment &gt; 3 months

          -  The patients of normal BP, or hypertensive patients receiving antihypertensive
             medication, Seated systolic blood pressure (SeSBP) is between 120-180mmHg and the
             Seated diastolic blood pressure (SeDBP) is between 80-110mmHg;

          -  Evidence of albuminuria defined as an AER of 20 and 500 ug/minute on a single timed
             overnight collection. Before randomization the patient must quality with two AERs of 3
             days intervals in the absence of confounding factors such as urinary tract infection,
             acute febrile illness and cardiac failure. The two AERs measurement should be in the
             above defined range and the variability between the two AERs measurement must be &lt;35%.
             Value of basal AER is calculated as the mean of the 2 measurements. The UAER measured
             using immunity nephelometer method (DCA2000);

          -  Serum creatinine &lt; 150umol/L(1.7mg/dl) and serum potassium in the normal lab range
             (3.5-5.5 mol/L);

          -  18 Kg/m2less than or equal to BMI less than or equal to 35Kg/m2

        Exclusion Criteria:

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Thoenes</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>November 22, 2007</last_update_submitted>
  <last_update_submitted_qc>November 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

